Leiden, The Netherlands, 12 November 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced that Berna Biotech AG, its wholly owned subsidiary, has sold all the 2.9 million shares it owned in Pevion Biotech Ltd, Bern (Switzerland) to other shareholders of Pevion Biotech. This number of shares represents 36 percent of Pevion Biotech's capital and results in net proceeds for Crucell of approximately CHF 10 million (€ 6 million).
"This transaction is further proof that we are committed to focus on the strengths of our core business", said Crucell's Chief Financial Officer, Leonard Kruimer.